Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EpCam-Scan
NCT07784660Phase 1Enrolling by invitation
- Sponsor
- Tomsk National Research Medical Centre of the Russian Academy of Sciences
- Start
- Jun 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [99mTc]Tc-DARPinEc1-G3C in breast cancer, sponsored by Tomsk National Research Medical Centre of the Russian Academy of Sciences. Primary endpoints: Gamma camera-based whole-body [99mTc]Tc-DARPinEc1-G3C uptake value at 6 hours, SPECT-based [99mTc]Tc-DARPinEc1-G3C uptake value in tumor lesions at 6 hours and 2 more. Started Jun 2026; status: enrolling by invitation.
02
Drugs
[99mTc]Tc-DARPinEc1-G3C
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07784660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07784660.